Physician profile
Amy B Davis
NPI 1184755308
$378.05
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.90 · 2020: $20.36 · 2021: $94.95 · 2022: $170.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $117.39 | 2022 | |
| Janssen Pharmaceuticals, INC | $87.68 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $53.04 | 2019 | |
| Baxter Healthcare | $39.86 | 2019 | |
| Gilead Sciences, INC. | $21.21 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.91 | 2022 | |
| Abbott Laboratories | $20.58 | 2021 | |
| Pfizer INC. | $17.38 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.